Hostname: page-component-7b7567c8c-2rsb6 Total loading time: 0 Render date: 2026-11-12T20:25:58.801Z Has data issue: false hasContentIssue false
  • English
  • Français

New Approaches in Managing Chronic Insomnia

Published online by Cambridge University Press:  07 November 2014

David N. Neubauer
David N. Neubauer*
Affiliation:
David N. Neubauer, MD, is assistant professor in the Department of Psychiatry at, Johns Hopkins University School of Medicineand medical director of the Psychiatry Mobile Treatment Services at Johns Hopkins Bayview Medical Center in Baltimore, Maryland. He is also associate director of the Johns Hopkins Sleep Disorders Center.
Get accessRights & Permissions [Opens in a new window]

Abstract

Despite a high prevalence in the United States, insomnia remains underdiagnosed and undertreated. Extensive research has identified several factors that contribute to the inadequate treatment of insomnia, including the failure of patients to report insomnia to physicians, limited physician training, and physicianmisconceptions about the risks associated with hypnotic medications. Toachieve optimal patient outcomes, physicians differentiate acute from chronic insomnia and distinguish primary insomnia from sleep disorders that occur with comorbid conditions, most notably psychiatric illnesses such as circadian rhythm disturbances. In addition, they utilize sleep hygiene measures, behavioral therapy, and/or pharmacologic medications to improve sleep problems in patients with insomnia. Newer nonbenzodiazepine receptor agonists are effective with fewer side effects than older benzodiazepine agonists; however, in 2005 a National Institutes of Health panel on chronic insomnia management indicated that clinical trials are needed to establish the long-term benefits of the newer drugs. Since 2005, data from clinical trials lasting 6 months to 1 year have been published for hypnotics including eszopiclone, zaleplon, and zolpidem extended-release. As the result of potentially altered dosing and monitoring, elderly patients require special consideration.

Information

Type
Research Article
Information
CNS Spectrums , Volume 11 , Issue S8 , 2006, pp. 1 - 16
Copyright
Copyright © Cambridge University Press 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1.National Institutes of Health. National Institutes of Health state of the science conference statement on manifestations and management of chronic insomnia in adults. Sleep. 2005;28:1049–1057.CrossRefGoogle Scholar
2.Shochat, T, Umphress, J, Ancoli-Israel, S. Insomnia in primary care patients. Sleep. 1999;22(S2):359–365.Google ScholarPubMed
3.Benca, RM. Diagnosis and treatment of chronic insomnia: A review. Psychiatr Serv. 2005;56:332–343.CrossRefGoogle ScholarPubMed
4.Leger, D, Poursain, B. An international survey of insomnia: Under-recognition and under-treatment of a polysymptomatic condition. Curr Med Res Opin. 2005;21:1785–1792.CrossRefGoogle ScholarPubMed
5.Sleep Disorders. In: Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text rev. Washington, DC: American Psychiatric Association; 1994:597–662.Google Scholar
6.National Heart, Lung, and Blood Institute, National Institutes of Health. Insomnia: Assessment and management in primary care. www.nhlbi.nih.gov/health/prof/sleep/insom_pc.pdf. Accessed January 9, 2006.Google Scholar
7.Ohayon, MM, Paiva, T. Global sleep dissatisfaction for the assessment of insomnia severity in the general population of Portugal. Sleep Med. 2005;6:435–441.CrossRefGoogle ScholarPubMed
8.Katz, DA, McHorney, CA. The relationship between insomnia and health-related quality of life in patients with chronic illness. J Fam Pract. 2002;51:229–235.Google ScholarPubMed
9.Kupfer, DJ. Pathophysiology and management of insomnia during depression. Ann Clin Psychiatry. 1999;11:267–276.CrossRefGoogle ScholarPubMed
10.Breslau, N, Roth, T, Rosenthal, L, Andreski, P. Sleep disturbance and psychiatric disorders: A longitudinal epidemiological study of young adults. Biol Psychiatry. 1996;39:411–418.CrossRefGoogle ScholarPubMed
11.Ford, DE, Kamerow, DB. Epidemiologic study of sleep disturbances and psychiatric disorders. JAMA. 1989;262:1479–1484.CrossRefGoogle ScholarPubMed
12.Edinger, JD, Wohlgemuth, WK, Radtke, RA, Marsh, GR, Quillian, RE. Cognitive behavioral therapy for treatment of chronic primary insomnia. A randomized controlled trial. JAMA. 2001;285:1856–1864.CrossRefGoogle ScholarPubMed
13.Greeff, O. Good night—do patients really sleep well on all hypnotics? www.medpharm.co.za/safp/2001/nov/goodnight.html. Accessed November 1, 2005.Google Scholar
14.Greenblatt, DJ. Pharmacokinetic determinants of hypnotic drug action: The art and science of controlling release. Sleep Med. 2006 May 12; [Epub ahead of print] doi:10.1016/j.sleep.2006.03.002.Google Scholar
15.Avidan, AY, Fries, BE, James, ML, Szafara, KL, Wright, GT, Chervin, RD. Insomnia and hypnotic use, recorded in the minimum data set, as predictors of falls and hip fractures in Michigan nursing homes. J Am Geriatr Soc. 2005;53:955–962.CrossRefGoogle ScholarPubMed
16.Holbrook, A, Crowther, R, Lotter, A, Cheng, C, King, D. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ. 2000;162:225–233.Google ScholarPubMed
17.Dawson, GR, Collinson, N, Atack, JR. Development of subtype selective GABAA modulators. CNS Spectr. 2005;10:21–27.CrossRefGoogle ScholarPubMed
18.Roth, T, Soubrane, C, Titeux, L, Walsh, J, on behalf of the zoladult study group. Efficacy and safety of zolpidem-MR: A double-blind, placebo-controlled study in adults with primary insomnia. Sleep Med. In press.Google Scholar
19.Weinling, E, McDougall, S, Andre, F, Bianchetti, G, Dubruc, C. Pharmacokinetic profile of a new modified release formulation of zolpidem designed to improve sleep maintenance. Fundam Clin Pharmacol. 2006;20:397–403.CrossRefGoogle ScholarPubMed
20.Perlis, ML, McCall, WV, Krystal, AD, Walsh, JK. Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia. J Clin Psychiatry. 2004;65:1128–1137.CrossRefGoogle ScholarPubMed
21.Erman, M, Krystal, A, Zammit, G, Soubrane, C, Roth, T, on behalf of the Zolong study group. Zolpidem extended-release 12.5-mg, taken for 24 weeks “as needed” up to 7 nights/week improves subjective measures of therapeutic global impression, sleep onset, and sleep maintenance in patients with chronic insomnia. Int J Neuropsychopharmacol. 2006;9(suppl 2):S251.Google Scholar
22.Blin, O, Micallef, J, Audebert, C, Legangneux, E. A double-blind, placebo- and flurazepam-controlled investigation of the residual psychomotor and cognitive effects of modified-release zolpidem in young healthy volunteers. J Clin Pharmacol. 2006;26:284–289.Google ScholarPubMed
23.Ancoli-Israel, S, Richardson, GS, Mangano, RM, Jenkins, L, Hall, P, Jones, WS. Long-term use of sedative hypnotics in older patients with insomnia. Sleep Med. 2005;6:107–113.CrossRefGoogle ScholarPubMed
24.Roth, T, Walsh, JK, Krystal, A, Wessel, T, Roehrs, TA. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med. 2005;6:487–495.CrossRefGoogle ScholarPubMed
25.McGechan, A, Wellington, K. Ramelteon. CNS Drugs. 2005;19:1057–1065.CrossRefGoogle ScholarPubMed
26.Physicians' Desk Reference. 60th ed. Montvale, NJ: Thomson PDR; 2006: 1686–1690, 2867–2871, 3228–3231.Google Scholar
27.Moen, MD, Plosker, GL. Zolpidem extended-release. CNS Drugs. 2006;20:419–426.CrossRefGoogle ScholarPubMed
28.Fava, M, McCall, WV, Krystal, A, et al.Eszopiclone Co-Administered With Fluoxetine in Patients With Insomnia Coexisting With Major Depressive Disorder. Biol Psychiatry. 2006;59:1052–1060.CrossRefGoogle ScholarPubMed
29.Asnis, GM, Charkraburtty, A, DuBoff, EA, et al.Zolpidem for persistent insomnia in SSRI-treated depressed patients. J Clin Psychiatry. 1999;60:668–676.CrossRefGoogle ScholarPubMed
30. Author unlisted. Health Care Sector Overview. New York, NY; Cowen and Company: April 7, 2006.Google Scholar
31.Mendelson, W. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry. 2005;66:469–476.CrossRefGoogle ScholarPubMed
32.Walsh, JK, Erman, M, Erwin, CR, et al.Subjective hypnotic efficacy of trazodone and zolpidem in DSMIII-R primary insomnia. Hum Psychopharmacol. 1998;13:191–198.3.0.CO;2-X>CrossRefGoogle Scholar
33.George, CF. Perspectives on the management of insomnia in patients with chronic respiratory disorders. Sleep. 2000;23(suppl 1):S31–S35.Google ScholarPubMed
34.Bailes, S, Baltzan, M, Alapin, I, Fichten, C, Libman, E. Diagnostic indicators of sleep apnea in older women and men: A prospective study. J Psychosom Res. 2005;59:365–373.CrossRefGoogle ScholarPubMed
35.Westbrook, PR, Levendowski, DJ, Cvetinovic, M, et al.Description and validation of the apnea risk evaluation system. A novel method to diagnose sleep apnea-hypopnea in the home. Chest. 2005;128:2166–2175.CrossRefGoogle ScholarPubMed